STR001-IT + STR001-ER

STR001-IT + STR001-ER is a combination therapy for sudden sensorineural hearing loss (SSNHL) consisting of two formulations of the investigational drug STR001, which is **pioglitazone repurposed as a small molecule agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma)**. STR001-IT is a thermogel administered by intratympanic injection, and STR001-ER is an extended-release tablet for oral administration. The drug exerts **anti-inflammatory and antioxidant effects in cochlear tissues** by targeting PPAR-gamma, aiming to protect auditory hair cells and promote restoration of hearing after sudden deafness events. Developed by Strekin AG, the combination is being assessed as the first pharmacological therapy to potentially restore hearing in patients with acute hearing loss events[1][2][3][4][6][8][10].

Other names

STR001-ITSTR-001-ITSTR 001-ITSTR001-ERSTR-001-ERSTR 001-ER